


Remarks

In response to the Notification of Defective Response having a mailing date of June 10, 2002, Applicants have prepared this amendment to direct the insertion of the "Sequence Listing" into the specification.

Applicants respectfully assert that all amendments are fairly based on the specification, and respectfully request their entry.

Early and favorable consideration is requested.


Respectfully submitted,


Royal N. Ronning, Jr. 32,529
Attorney for Applicants

Amersham Biosciences Corp.
800 Centennial Avenue
P. O. Box 1327
Piscataway, NJ 08855-1327

Tel: (732) 457-8423
Fax: (732) 457-8463

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on 27 June 02.

Melissa Leck
Signature 
Date June 27, 2002

PA9816.ST25
SEQUENCE LISTING

<110> Storey, Anthony E
Mendizabal, Marivi
Champion, Susan
Gibson, Alex
Guilbert, Benedicte
Wilson, Ian A
Knox, Peter

<120> Labelled Glutamine and Lysine Analogues

<130> PA-9816

<140> 09/674,616

<141> 1999-05-14

<150> PCT/GB99/01550

<151> 1999-05-14

<150> EP 98303872.0

<151> 1998-05-15

<160> 29

<170> PatentIn version 3.1

<210> 1

<211> 12

<212> PRT

<213> synthetic peptide

<400> 1

| | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asn | Gln | Glu | Gln | Val | Ser | Pro | Tyr | Thr | Leu | Leu | Lys |
| 1 | | | | 5 | | | | | 10 | | |

<210> 2

<211> 13

<212> PRT

<213> synthetic peptide

<400> 2

| | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asn | Gln | Glu | Gln | Val | Ser | Pro | Tyr | Thr | Leu | Leu | Lys | Gly |
| 1 | | | | 5 | | | | | 10 | | | |

PA9816.ST25

<210> 3
 <211> 13
 <212> PRT
 <213> synthetic peptide

<400> 3

| | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asn | Gln | Glu | Ala | Val | Ser | Pro | Tyr | Thr | Leu | Leu | Lys | Gly |
| 1 | | | | 5 | | | | | 10 | | | |

<210> 4
 <211> 13
 <212> PRT
 <213> synthetic peptide

<400> 4

| | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asn | Ala | Glu | Ala | Val | Ser | Pro | Tyr | Thr | Leu | Leu | Lys | Gly |
| 1 | | | | 5 | | | | | 10 | | | |

<210> 5
 <211> 13
 <212> PRT
 <213> synthetic peptide

<400> 5

| | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asn | Gln | Gln | Gln | Val | Ser | Pro | Tyr | Thr | Leu | Leu | Lys | Gly |
| 1 | | | | 5 | | | | | 10 | | | |

<210> 6
 <211> 3
 <212> PRT
 <213> synthetic peptide

<400> 6

| | | |
|-----|-----|-----|
| Asn | Gln | Gly |
| 1 | | |

<210> 7
 <211> 6
 <212> PRT

PA9816.ST25

<213> synthetic peptide

<400> 7

Asn Gln Glu Gln Val Gly
1 5

<210> 8

<211> 9

<212> PRT

<213> synthetic peptide

<400> 8

Asn Gln Glu Gln Val Ser Pro Tyr Gly
1 5

<210> 9

<211> 13

<212> PRT

<213> synthetic peptide

<400> 9

Asn Gln Glu Gln Val Ser Pro Leu Thr Leu Leu Lys Gly
1 5 10

<210> 10

<211> 13

<212> PRT

<213> synthetic peptide

<220>

<221> MISC_FEATURE

<222> (8)..(8)

<223> MISC_FEATURE "Xaa" = 2-naphthylalanine

<400> 10

Asn Gln Glu Gln Val Ser Pro Xaa Thr Leu Leu Lys Gly
1 5 10

<210> 11

PA9816.ST25

<211> 13
 <212> PRT
 <213> synthetic peptide

<220>
 <221> MISC_FEATURE
 <222> (8)..(8)
 <223> MISC_FEATURE "Xaa" = pBr-Phe

<400> 11

| | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asn | Gln | Glu | Gln | Val | Ser | Pro | Xaa | Thr | Leu | Leu | Lys | Gly |
| 1 | | | | 5 | | | | | 10 | | | |

<210> 12
 <211> 13
 <212> PRT
 <213> synthetic peptide

<220>
 <221> MISC_FEATURE
 <222> (8)..(8)
 <223> MISC_FEATURE "Xaa" = I-Tyr

<400> 12

| | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asn | Gln | Glu | Gln | Val | Ser | Pro | Xaa | Thr | Leu | Leu | Lys | Gly |
| 1 | | | | 5 | | | | | 10 | | | |

<210> 13
 <211> 13
 <212> PRT
 <213> synthetic peptide

<220>
 <221> MISC_FEATURE
 <222> (8)..(8)
 <223> MISC_FEATURE "Xaa" = I2-Tyr

<400> 13

| | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asn | Gln | Glu | Gln | Val | Ser | Pro | Xaa | Thr | Leu | Leu | Lys | Gly |
| 1 | | | | 5 | | | | | 10 | | | |

PA9816.ST25

<210> 14
 <211> 13
 <212> PRT
 <213> synthetic peptide

<220>
 <221> MISC_FEATURE
 <222> (12)..(12)
 <223> MISC_FEATURE "Xaa" = D-Lys

<400> 14

| | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asn | Gln | Glu | Gln | Val | Ser | Pro | Tyr | Thr | Leu | Leu | Xaa | Gly |
| 1 | | | | 5 | | | | | 10 | | | |

<210> 15
 <211> 13
 <212> PRT
 <213> synthetic peptide

<220>
 <221> MISC_FEATURE
 <222> (8)..(8)
 <223> MISC_FEATURE "Xaa" = D-Tyr

<220>
 <221> MISC_FEATURE
 <222> (12)..(12)
 <223> MISC_FEATURE "Xaa" = D-Lys

<400> 15

| | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asn | Gln | Glu | Gln | Val | Ser | Pro | Xaa | Thr | Leu | Leu | Xaa | Gly |
| 1 | | | | 5 | | | | | 10 | | | |

<210> 16
 <211> 13
 <212> PRT
 <213> synthetic peptide

<220>

PA9816.ST25

<221> MISC_FEATURE
<222> (6)..(6)
<223> MISC_FEATURE "Xaa" = D-Ser

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> MISC_FEATURE "Xaa" = D-Tyr

<220>
<221> MISC_FEATURE
<222> (12)..(12)
<223> MISC_FEATURE "Xaa" = D-Lys

<400> 16

Asn Gln Glu Gln Val Xaa Pro Xaa Thr Leu Leu Xaa Gly
1 5 10

<210> 17
<211> 13
<212> PRT
<213> synthetic peptide

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> MISC_FEATURE "Xaa" = D-Val

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> MISC_FEATURE "Xaa" = D-Ser

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> MISC_FEATURE "Xaa" = D-Tyr

<220>
<221> MISC_FEATURE

PA9816.ST25

<222> (12)..(12)

<223> MISC_FEATURE "Xaa" = D-Lys

<400> 17

| | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asn | Gln | Glu | Gln | Xaa | Xaa | Pro | Xaa | Thr | Leu | Leu | Xaa | Gly |
| 1 | | | | 5 | | | | | 10 | | | |

<210> 18

<211> 13

<212> PRT

<213> synthetic peptide

<220>

<221> MISC_FEATURE

<222> (1)..(1)

<223> MISC_FEATURE "Xaa" = D-Asn

<220>

<221> MISC_FEATURE

<222> (8)..(8)

<223> MISC_FEATURE "Xaa" = D-Tyr

<220>

<221> MISC_FEATURE

<222> (12)..(12)

<223> MISC_FEATURE "Xaa" = D-Lys

<400> 18

| | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Xaa | Gln | Glu | Gln | Val | Ser | Pro | Xaa | Thr | Leu | Leu | Xaa | Gly |
| 1 | | | | 5 | | | | | 10 | | | |

<210> 19

<211> 13

<212> PRT

<213> synthetic peptide

<220>

<221> MISC_FEATURE

<222> (8)..(8)

<223> MISC_FEATURE "Xaa" = D-Tyr

PA9816.ST25

<220>
 <221> MISC_FEATURE
 <222> (13)..(13)
 <223> MISC_FEATURE "Xaa" = beta-Ala

<220>
 <221> MISC_FEATURE
 <222> (12)..(12)
 <223> MISC_FEATURE "Xaa" = D-Lys

<400> 19

| | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asn | Gln | Glu | Gln | Val | Ser | Pro | Xaa | Thr | Leu | Leu | Xaa | Xaa |
| 1 | | | | 5 | | | | | 10 | | | |

<210> 20
 <211> 12
 <212> PRT
 <213> synthetic peptide

<220>
 <221> MISC_FEATURE
 <222> (7)..(7)
 <223> MISC_FEATURE "Xaa" = D-Tyr

<220>
 <221> MISC_FEATURE
 <222> (11)..(11)
 <223> MISC_FEATURE "Xaa" = D-Lys

<400> 20

| | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Gln | Glu | Gln | Val | Ser | Pro | Xaa | Thr | Leu | Leu | Xaa | Gly |
| 1 | | | | 5 | | | | 10 | | | |

<210> 21
 <211> 13
 <212> PRT
 <213> synthetic peptide

PA9816.ST25

<220>
 <221> MISC_FEATURE
 <222> (5)..(12)
 <223> MISC_FEATURE = D-amino acids

<400> 21

| | | | | | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Asn | Gln | Glu | Gln | Val | Ser | Pro | Tyr | Thr | Leu | Leu | Lys | Gly |
| 1 | | | | 5 | | | | | 10 | | | |

<210> 22
 <211> 9
 <212> PRT
 <213> synthetic peptide

<220>
 <221> MISC_FEATURE
 <222> (2)..(9)
 <223> MISC_FEATURE = D-amino acids

<400> 22

| | | | | | | | | |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Gly | Lys | Leu | Leu | Thr | Tyr | Pro | Ser | Val |
| 1 | | | | 5 | | | | |

<210> 23
 <211> 9
 <212> PRT
 <213> synthetic peptide

<220>
 <221> MISC_FEATURE
 <222> (5)..(5)
 <223> MISC_FEATURE "Xaa" = D-Val

<220>
 <221> MISC_FEATURE
 <222> (6)..(6)
 <223> MISC_FEATURE "Xaa" = O-methyl serine

<400> 23

PA9816.ST25

Asn Gln Gln Gln Xaa Xaa Pro Leu Gly
1 5

<210> 24
<211> 13
<212> PRT
<213> synthetic peptide

<400> 24

Asn Gln Glu Gln Val Ser Pro Tyr Ala Ala Ala Gly
1 5 10

<210> 25
<211> 10
<212> PRT
<213> synthetic peptide

<400> 25

Leu Gly Pro Gly Gln Ser Lys Val Ile Gly
1 5 10

<210> 26
<211> 6
<212> PRT
<213> synthetic peptide

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> MISC_FEATURE "Xaa" = pyro-Glu

<400> 26

Xaa Ala Gln Ile Val Gly
1 5

<210> 27
<211> 12
<212> PRT
<213> synthetic peptide

PA9816.ST25

<400> 27

Leu Glu Phe Asp Thr Gln Ser Lys Asn Ile Leu Gly
1 5 10

<210> 28

<211> 7

<212> PRT

<213> synthetic peptide

<400> 28

Gly Gln Asp Pro Val Lys Gly
1 5

<210> 29

<211> 12

<212> PRT

<213> synthetic peptide

<400> 29

Tyr Glu Val His His Gln Lys Leu Val Phe Phe Gly
1 5 10